ArticleFrontiers in medicine2025
Time series prediction for lung disease diagnosis and treatment optimization.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To address these limitations, this study proposes a novel AI-driven solution for time series prediction in lung disease diagnosis and treatment optimization. Methods: At the core of our framework lies PulmoNet, an anatomically-constrained, multi-scale neural architecture designed to learn structured, interpretable representations of lung-related pathologies. Unlike generic models, PulmoNet integrates bronchopulmonary anatomical priors and leverages spatial attention mechanisms to focus on critical parenchymal and vascular regions, which are often associated with early pathological changes. It also embeds hierarchical features from CT and X-ray modalities, capturing both macro-level anatomical landmarks and micro-level lesion textures. Furthermore, it constructs a latent inter-lobar graph to model spatial dependencies and anatomical adjacencies, enabling joint segmentation, classification, and feature attribution. Results: This structured approach enhances both diagnostic performance and interpretability. Complementing this architecture, we introduce APIL (Adaptive Patho-Integrated Learning)-a two-stage, curriculum-based learning strategy that incorporates radiological priors, rule-based constraints, and multi-view consistency to improve model generalization and clinical alignment. Discussion: APIL dynamically adjusts the learning complexity by introducing prior-informed pseudo-labels, anatomical masks, and contrastive consistency losses across views. It effectively combines weak supervision, domain adaptation, and uncertainty modeling, making it particularly adept at learning from sparse, noisy, or imbalanced datasets commonly found in clinical environments. Ultimately, this integrated framework offers a clinically meaningful, anatomically coherent, and data-efficient solution for next-generation pulmonary disease modeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.